Bristol-Myers Squibb Company (NYSE:BMY) changes shares on Wednesday trading session, with a change of 0.37% or $0.22 shares. The trading starts at $59.95 and closed at $59.47 throughout the day. The trading session low price was $59.41 and day high was $60.38 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 10.66 million while its average volume is 14.27M. In other hand, the BMY market cap reached to $135.54B. While, its current target price is $71.67.
On July 6, 2020, BRIEF-Dragonfly Therapeutics Announces Research Collaboration With Bristol Myers Squibb. According to the news reported on Reuters, * DRAGONFLY THERAPEUTICS ANNOUNCES NEW RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB TO DEVELOP NOVEL THERAPEUTIC CANDIDATES FOR MULTIPLE SCLEROSIS AND NEURO-INFLAMMATION TARGET
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 0.91% and down -1.00% for month. Its quarterly performance was -2.36% below, while its half year performance is down -9.00%. BMY yearly performance stood at positive 30.64% and fall -7.01% for year-to-date. Current recommendation for Bristol-Myers Squibb Company is 1.90.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BMY EPS (TTM) for 12-month is 0.81. EPS for this year is -33.90%, while for the next year its value is 7.39. Sales growth for the current quarter is 3.36 while its EPS Q/Q reached -132.90%. It has an EPS of 10.90% up for past five years and for the next five years will be up 21.95%.
Let’s take a look on the analyst recommendations on BMY for the current month and previous month. For the current month, 9 of 17 analysts recommend stock as Buy while 0 as Sell, 3 as overweight, 0 as underweight and 5 as Hold. As compared with the previous month ratings, 16 analysts participate in stock recommendation. Out of 16, 0 rated it sell, 9 rated it as Buy and 5 as Hold Ratings. On the other hand, target price ranges from $62.00 – $81.00. Average target price for BMY was reached at $71.67.
The insider ownership moved to 0.10% and institutional holding shifted to 77.10%.
The company posted an EPS (TTM) of 0.81. According to the most recent quarter report on (Jun 2020), 12 analysts estimated an average EPS of 1.48, while 1.18 EPS posted a year ago period. Analyst Estimated EPS for BMY published in the report was $1.38 – $1.62 during the same period. Comparing with last year, the average estimated EPS was 1.18 which is lower than 1.72 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BMY fall -0.35% for period of 200 days. SMA for 50 days was 1.35% which is showing green signal, while SMA-20 was 1.23%. The moving average value for Bristol-Myers Squibb Company (BMY) is 30.59M and 1.01% for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BMY stock. On Jun 15, Paliwal Dinesh C, Director, bought 9,174 trading shares at the cost of $54.50, which valued at 0.5 million. On May 22, Dubow Adam, SVP,ChiefCompliance&EthicsOff., sold 3,200 shares at the cost of $61.01, with total shares of 16,086. On May 19, Schmukler Louis S, EVP,Pres.,Glob.Prod. & Supply, sold 25,000 shares at the cost of 62.68. After this transaction, Schmukler Louis S total shares reached to 26,777 which valued at 1.57 million.